An Open-label, Single-sequence Study in Two Cohorts of Healthy Subjects to Evaluate the Single-dose Pharmacokinetics of Tasimelteon Alone and in Combination With a CYP3A4 Inhibitor, Ketoconazole, or a CYP3A4 Inducer, Rifampin.

Trial Profile

An Open-label, Single-sequence Study in Two Cohorts of Healthy Subjects to Evaluate the Single-dose Pharmacokinetics of Tasimelteon Alone and in Combination With a CYP3A4 Inhibitor, Ketoconazole, or a CYP3A4 Inducer, Rifampin.

Completed
Phase of Trial: Phase I

Latest Information Update: 04 Sep 2012

At a glance

  • Drugs Tasimelteon (Primary) ; Ketoconazole; Rifampicin
  • Indications Bacterial infections; Circadian rhythm sleep disorders; Insomnia; Major depressive disorder
  • Focus Pharmacokinetics
  • Most Recent Events

    • 01 Aug 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 23 Jul 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 18 Jul 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top